Q-Line Biotech Ltd.
SMEBSE₹326–343
₹ 153 Cr
800 Shares
₹ 2,60,800
₹10
Financial Summary
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| 31,378.04 | 20,364.61 | |
| 880.38 | 280.2 | |
| 32,258.42 | 20,644.81 | |
| 23,929.3 | 16,558.35 | |
| 4,419.23 | 3,060.17 | |
| 2,451.37 | 2,164.21 |
Subscription Details
IPO Timeline
IPO Offer Start
21 May 2026
IPO Offer Ends
25 May 2026
29 May 2026
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | To meet Working Capital requirements | 935 |
| 2 | Repayment of certain borrowing availed by our Company, in part or full | 900 |
| 3 | General Corporate Purpose | 50.972 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
96.77%
Promoter stake
Post-IPO
67.51%
Promoter stake
Offered to Public
44,72,000
shares
Post Share Capital
1,57,50,000
shares
About the Company
We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of Q-Line in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).
Use of Proceeds
1) To meet Working Capital requirements2) Repayment of certain borrowing availed by our Company, in part or full3) General Corporate Purpose.